BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time.
The financial results and live webcast will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com.
Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call.
To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this link. The access code for the call is 462066.
A replay of the conference call will be posted shortly after the call and will be available for seven days.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711590201/en/
Contacts
Investor Contact
Anthony DiMeo
VP, Investor Relations & Media
anthony.dimeo@amneal.com
Source: Amneal Pharmaceuticals, Inc.
